The only major event I could possibly imagine that would get this company back on track is the replacement of the CEO. He has just made too many poor decisions and there is no evidence to prove future decisions will be any better.
His communication skills are, at best, poor. As a strategist, he has no map. He also has no past record of guiding a company to its full potential.
The problem is Brad is the current Chairman and CEO. The board is impotent. The major stockholder has sold out. Who is left to make the intelligent tough decisions? No one.
Unless one of the non-H&N trials reports out better than currently anticipated, this company and we as investors are toast!
It's tough to see a technology and company dwindle to worthless because management is not up to standard. His presence also impairs the future of patients that could have benefitted from REO.
What is the short case? It must be powerful for short sellers to remain short in the face of Dr. Frost adding to his position every day.
Right or wrong can anyone enlighten us to the short case?
It's a bit difficult to assess the impact of recent events on BRCA test revenues. Some will come from reduced payment by healthcare insurers. Possibly much more will come from the ability of competitors able to offer a competing test now that BRCA is no longer a protected target.
Has anyone seen a comprehensive report addressing the above?
There is no question in my mind that the drug has positive attributes. What is needed is a management team that can isolate the benefits, properly design a trial to statistically tease out the benefits and take the company to the next step.
Brad Thompson is just not the right guy to be running this company. He mismanages everything he touches. He seems like a nice enough guy, but, we don't need nice, we need competent.
I'm afraid we'll soon see him mismanage an offering of stock.
On what do you base your comments? For the past 2 years management has been hinting something great was coming. In Texas they refer to that as "all hat - no horse."
How long are the big investors going to allow the management to take big salaries and produce nothing?
This is one of the worst managements I have ever seen.
Does anyone know if they will be presenting next week at JP Morgan?
They need a bit more visibility and JPM would be a great venue for them.